Will the Phase 2 trial "Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients" reach primary completion on or before Sep 1, 2026?

Resolves Yes if ClinicalTrials.gov record NCT07043894 (Cancer Institute and Hospital, Chinese Academy of Medical Sciences) shows an actual primary completion date on or before Sep 1, 2026. Registered date at generation: Sep 1, 2026.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Sep 1, 2026, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.